Eikon Therapeutics/$EIKN
1D1W1MYTD1Y5YMAX
About Eikon Therapeutics
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
- Ticker
- $EIKN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 384
- Headquarters
- Millbrae, United States
- Website
- eikontx.com
EIKN Metrics
BasicAdvanced
$599M
-
-$13.73
-
-
Price and volume
Market cap
$599M
52-week high
$17.40
52-week low
$7.90
Average daily volume
342K
Financial strength
Current ratio
9.892
Quick ratio
9.606
Long term debt to equity
52.042
Total debt to equity
54.066
Interest coverage (TTM)
-375.30%
Profitability
EBITDA (TTM)
-292.913
Management effectiveness
Valuation
Price to book
1.28
Price to tangible book (TTM)
1.28
Price to free cash flow (TTM)
-1.001
Free cash flow yield (TTM)
-99.91%
Free cash flow per share (TTM)
-11.04
Growth
What the Analysts think about EIKN
Analyst ratings (Buy, Hold, Sell) for Eikon Therapeutics stock.
EIKN Financial Performance
Revenues and expenses
EIKN Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.